Value
7.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 7.5 |
- ▸Attractively valued
ANRO · Why this verdict
Why Alto Neuroscience (ANRO) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Business quality sits well below the minimum threshold required for a position, reflecting cash burn, no competitive moat, and a weak Piotroski F-Score of 2 out of 9. Bear case | The quality score should recover above the 4.0 floor over the next 12 months as the underlying profitability, leverage, and efficiency components improve. | →Stable |
| CounterA weak Piotroski score alongside ongoing cash burn is typical for a clinical-stage biotech pre-commercialization, so the quality gap may persist by design rather than reflect distress. | ||
The chart has confirmed a bullish breakout, with a golden cross, shares above all major moving averages, and a bullish MACD reading. Chart pattern detection | The breakout should hold, with shares continuing to trade above their key moving averages over the next 12 months. | →Stable |
| CounterOn-balance volume is already showing a distribution pattern even as price holds the breakout, a divergence that can precede a failed breakout. | ||
On-balance volume is falling even as the stock trades above its 200-day average, a distribution-style divergence that raises the risk the recent breakout lacks genuine buying support. Momentum breakdown | Volume flows should shift back to accumulation over the next 12 months, confirming the breakout with genuine buying pressure. | →Stable |
| CounterThis divergence may simply reflect lower overall trading activity rather than active distribution, especially for a name with binary biotech-driven price action. | ||
Analyst price targets imply meaningful upside of roughly 42% from current levels. Sentiment breakdown | Analyst targets should hold or rise further over the next 12 months to sustain the implied upside. | →Stable |
| CounterFor a speculative biotech with a below-floor quality score, analyst targets can be cut sharply following a negative clinical or earnings update. | ||
Recent earnings results have been mixed, with two misses against two beats over the last four quarters, including the most recent quarter coming in as a large miss. Catalyst breakdown | The beat rate should improve to a majority-beat cadence over the next 12 months to support the broader investment case. | →Stable |
| CounterThe most recent quarter's miss was unusually large relative to estimates, which could signal accelerating rather than stabilizing volatility in results. | ||
Business quality sits well below the minimum threshold required for a position, reflecting cash burn, no competitive moat, and a weak Piotroski F-Score of 2 out of 9.
→StableBear case
- Expectation
- The quality score should recover above the 4.0 floor over the next 12 months as the underlying profitability, leverage, and efficiency components improve.
CounterA weak Piotroski score alongside ongoing cash burn is typical for a clinical-stage biotech pre-commercialization, so the quality gap may persist by design rather than reflect distress.
The chart has confirmed a bullish breakout, with a golden cross, shares above all major moving averages, and a bullish MACD reading.
→StableChart pattern detection
- Expectation
- The breakout should hold, with shares continuing to trade above their key moving averages over the next 12 months.
CounterOn-balance volume is already showing a distribution pattern even as price holds the breakout, a divergence that can precede a failed breakout.
On-balance volume is falling even as the stock trades above its 200-day average, a distribution-style divergence that raises the risk the recent breakout lacks genuine buying support.
→StableMomentum breakdown
- Expectation
- Volume flows should shift back to accumulation over the next 12 months, confirming the breakout with genuine buying pressure.
CounterThis divergence may simply reflect lower overall trading activity rather than active distribution, especially for a name with binary biotech-driven price action.
Analyst price targets imply meaningful upside of roughly 42% from current levels.
→StableSentiment breakdown
- Expectation
- Analyst targets should hold or rise further over the next 12 months to sustain the implied upside.
CounterFor a speculative biotech with a below-floor quality score, analyst targets can be cut sharply following a negative clinical or earnings update.
Recent earnings results have been mixed, with two misses against two beats over the last four quarters, including the most recent quarter coming in as a large miss.
→StableCatalyst breakdown
- Expectation
- The beat rate should improve to a majority-beat cadence over the next 12 months to support the broader investment case.
CounterThe most recent quarter's miss was unusually large relative to estimates, which could signal accelerating rather than stabilizing volatility in results.
TrendMatrix Research · core thesis
Engine thesis — one sentence
ANRO has confirmed a bullish technical breakout with meaningful analyst-implied upside, but quality sitting well below the required floor, a volume-distribution divergence, and a choppy earnings track record keep this a speculative biotech name.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 5.8 |
- ▸Overbought (RSI 70)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.3 |
| Price target | 8.9 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 35%
Insider
7.5/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 4.5 |
| growth rank | 5.0 |
Technical
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.7 |
| support resistance | 2.1 |
| 52w position | 8.3 |
Risk (lower is worse)
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.2 |
| days to cover | 5.9 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 6.7 |
| debt equity | 9.6 |
- ▸Elevated put/call: 13.38
- ▸High IV: 144%
- ▸Above max pain $18
Catalyst
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:7.9>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:35d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.1<1.5@spot
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
1.14
Upside
+17.1%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.9B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Momentum at 7.9 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:1.1<1.5@spot.
The strongest dimensions are Momentum at 7.9, Sentiment at 7.6, and Value at 7.5; the weakest are Quality at 1.6, Catalyst at 3.3, and Risk (lower is worse) at 4.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 1.14 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Required Floor
Trip ifQuality score exceeds 4.0 from the current 1.2.
- P2Confirmed Breakout Momentum
Trip ifMomentum score falls below 3.0 from the current 5.3.
- P3Volume Distribution Divergence
Trip ifMomentum score rises above 7.5 from the current 5.3.
- P4Meaningful Analyst Upside
Trip ifAverage analyst price target falls by more than 30% from current levels.
- P5Choppy Earnings Track Record
Trip ifEarnings beat rate falls below 25% over the next 4 reported quarters.